MultiCell President Stephen Chang, Ph.D. to Present at SCIA Conference for National Small Cap Investor Community
Friday March 31, 4:47 pm ET
MultiCell President to Outline Proprietary Cell Therapeutics Technologies at Gathering of Investment Professionals
SAN DIEGO--(BUSINESS WIRE)--March 31, 2006--MultiCell Technologies, Inc. (OTCBB:MCET - News), a developer of therapeutics for the treatment of degenerative neurological diseases, metabolic and endocrinological disorders, and infectious diseases, today announced that Company President Stephen Chang will be a featured speaker at tomorrow's Southern California Investment Association (SCIA) Conference.
The SCIA meeting is scheduled to take place tomorrow, April 1, from 7:15 a.m. to 2 p.m. at the Orange County Airport Hilton, 18800 MacArthur Boulevard, Irvine, CA, across the street from the John Wayne Airport.
Dr. Chang will provide an overview of MultiCell's portfolio of proprietary therapeutic candidates and development goals. He will discuss the Company's initiatives to develop new therapeutic compounds to treat a variety of serious diseases and conditions, including multiple sclerosis and Type-1 diabetes.
"MultiCell has established the management and scientific team necessary to execute our strategic vision, and continued to expand our unique intellectual property portfolio," said Dr. Chang. "We feel the Southern California Investment Association will afford us an excellent opportunity to explain our compelling story to investment professionals and help accelerate the success of our business initiatives."
About Southern California Investment Association
SCIA National Small Cap Syndicate is a comprehensive national organization developed to facilitate stock support and capital formation for small and emerging-growth companies. The alliance consists of almost 200 influential member firms plus associates including NASD broker/ dealers, investment and merchant bankers, investment advisors, analysts, market makers, venture capitalists, fund managers, media and accredited investors.
About MultiCell Technologies, Inc.
MultiCell Technologies, Inc. is a biopharmaceutical company committed to the development of breakthrough therapeutics based on a portfolio of therapeutic candidates and patented drug development technology platforms. The Company's drug development programs are focused on modulation of the immune system. The Company's lead drug candidates include drugs to treat fatigue resulting from multiple sclerosis, relapse-remitting multiple sclerosis, and type-1 diabetes. Other therapeutic candidates in the MultiCell development pipeline include new antiviral treatments to address worldwide influenza threats as well as treatments for other infectious diseases. The Company also holds unique cell-based technology for use in drug discovery screening applications, and is a leading producer of the cell lines needed by the biotechnology industry to develop new drugs and therapeutics. For more information on MultiCell, please visit multicell.com.
Forward-Looking Statements
Any statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). These statements are often, but not always, made through the use of words or phrases such as "believe," "will," "expect," "anticipate," "estimate," "intend," "plan," "forecast," "could," and "would." Examples of such forward-looking statements include statements regarding contemplated guidance in the investment and financial markets, evaluation of the company's lead drug candidates, or commencement of clinical trials. MultiCell bases these forward-looking statements on current expectations about future events. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statements include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory approval, or successfully commercialize our lead drug candidates as expected, the market for our products will not grow as expected, and the risk that our products will not achieve expectations. For additional information about risks and uncertainties MultiCell faces, see documents MultiCell files with the SEC, including MultiCell's report on Form 10-KSB for the fiscal year ended November 30, 2004, and all our quarterly and other periodic SEC filings. MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and assumes no obligation and expressly disclaims any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.
Contact:MultiCell Technologies, Inc.
Gerard A. Wills, 858-200-0583
gwills@multicelltech.com
or
Trilogy Capital Partners (Financial Communications)
Paul Karon, 800-592-6067
paul@trilogy-capital.comSource: MultiCell Technologies, Inc.
biz.yahoo.com |
